Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity

Journal of Immunology

Volumn 171, Issue 11, 2003, Pages 5842-5852

  Van Den Broeke, Leon T ^a   Daschbach, Emily ^a   Thomas, Elaine K ^c   Andringa, Gerda ^b   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GANGLIOTETRAOSYLCERAMIDE ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 15; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL; CANCER PREVENTION; CARCINOGENESIS; CELL ACTIVITY; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; LUNG CARCINOMA; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY;

EID: 0345447651     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.11.5842     Document Type: Article

References (59)

1. Fernandez, N. C., A. Lozier, C. Flament, P. Ricciardi-Castagnoli, D. Bellet, M. Suter, M. Perricaudet, T. Tursz, E. Maraskovsky, and L. Zitvogel. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5:405.
2. Lanier, L. L. 1998. NK cell receptors. Annu. Rev. Immunol. 16:359.
3. Lanier, L. L. 2001. On guard-activating NK cell receptors. Nat. Immunol. 2:23.
4. Toura, I., T. Kawano, Y. Akutsu, T. Nakayama, T. Ochiai, and M. Taniguchi. 1999. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J. Immunol. 163:2387.
5. Worley, B. S., L. T. van den Broeke, T. Goletz, D. C. Pendleton, E. M. Daschbach, E. Thomas, F. M. Marincola, L. J. Helman, and J. A. Berzofsky. 2001. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 61:6868.
6. Mackall, C., J. Berzofsky, and L. J. Helman. 2000. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin. Orthop. 373:25.
7. Smiley, S. T., M. H. Kaplan, and M. J. Grusby. 1997. Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science 275:977.
8. Lutz, M. B., N. Kukutsch, A. L. J. Ogilvie, S. Robner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223:77.
9. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189:587.
10. Heitmann, S., T. Tschernig, M. Larbig, I. Steinmetz, H. J. Hedrich, and R. Pabst. 1999. Immunohistological characterization of leukocytes in the lungs of healthy mice and after bacterial intratracheal infection. Lab. Anim. 33:288.
11. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, and J. A. Berzofsky. 2000. Negative regulation of CTL-mediated tumour immunosurveillance through NKT cell induced IL-13 production and the IL-4R-STAT6 signal pathway. Nat. Immunol. 1:515.
12. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
13. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
14. Fields, R. C., K. Shimizu, and J. J. Mule. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:9482.
15. Albert, M. L., B. Sauter, and N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.
16. + T cells for efficient tumor cell lysis. Cancer Res. 60:4446.
17. Boczkowski, D., S. K. Nair, J. H. Nam, H. K. Lyerly, and E. Gilboa. 2000. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60:1028.
18. McArthur, J. G., and R. C. Mulligan. 1998. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J. Immunother. 21:41.
19. Specht, J. M., G. Wang, M. T. Do, J. S. Lam, R. E. Royal, M. E. Reeves, S. A. Rosenberg, and P. Hwu. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213.
20. Gong, J., D. Chen, M. Kashiwaba, and D. Kufe. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:558.
21. Kugler, A., G. Stuhler, P. Walden, G. Zoller, A. Zobywalski, P. Brossart, U. Trefzer, S. Ullrich, C. A. Muller, V. Becker, et al. 2000. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6:332.
22. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. DeLeo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
23. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
24. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
25. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
26. Pawlowska, A. B., S. Hashino, H. McKenna, B. J. Weigel, P. A. Taylor, and B. R. Blazar. 2001. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice. Blood 97:1474.
27. Yang, S., T. L. Darrow, C. E. Vervaert, and H. F. Seigler. 1997. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Cell. Immunol. 179:84.
28. DeMatosa, P., Z. Abdel-Wahaba, C. Vervaerta, and H. F. Seiglerb. 1998. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell. Immunol. 185:65.
29. Stout, R. D., G. A. Schwarting, and J. Suttles. 1987. Evidence that expression of asialo-GM1 may be associated with cell activation: correlation of asialo-GM1 expression with increased total cellular RNA and protein content in normal thymocyte and spleen cell populations. J. Immunol. 139:2123.
30. Suttles, J., G. A. Schwarting, and R. D. Stout. 1986. Flow cytometric analysis reveals the presence of asialo GM1 on the surface membrane of alloimmune cytotoxic T lymphocytes. J. Immunol. 136:1586.
31. + T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178:567.
32. Kalams, S. A., and B. D. Walker. 1998. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199.
33. + T cells. J. Exp. Med. 184:863.
34. Waldmann, T. A., and Y. Tagaya. 1999. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17:19.
35. Diehl, L., A. T. Den Boer, S. P. Schoenberger, E. I. H. van der Voort, T. N. M. Schumacher, C. J. M. Melief, R. Offringa, and R. E. M. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5:774.
36. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5:780.
37. Clark, E. A., and J. A. Ledbetter. 1994. How B and T cells talk to each other. Nature 367:425.
38. Turner, J. G., A. L. Rakhmilevich, L. Burdelya, Z. Neal, M. Imboden, P. M. Sondel, and H. Yu. 2001. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J. Immunol. 166:89.
39. Liu, Y., M. Qureshi, and J. Xiang. 2002. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells. Cancer Biother. Radiopharm. 17:11.
40. Noguchi, M., K. Imaizumi, T. Kawabe, H. Wakayama, Y. Horio, Y. Sekido, T. Hara, N. Hashimoto, M. Takahashi, K. Shimokata, and Y. Hasegawa. 2001. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-γ gene into lung cancer. Cancer Gene Ther. 8:421.
41. Nakajima, A., T. Kodama, S. Morimoto, M. Azuma, K. Takeda, H. Oshima, S. Yoshino, H. Yagita, and K. Okumura. 1998. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J. Immunol. 161:1901.
42. Gruber, T. A., D. C. Skelton, and D. B. Kohn. 2002. Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells. J. Immunol. 168:73.
43. Chambers, B. J., M. Salcedo, and H. G. Ljunggren. 1996. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 5:311.
44. Martin-Fontecha, A., E. Assarsson, E. Carbone, K. Karre, and H. G. Ljunggren. 1999. Triggering of murine NK cells by CD40 and CD86 (B7-2). J. Immunol. 162:5910.
45. Poggi, A., R. Carosio, G. M. Spaggiari, C. Fortis, G. Tambussi, G. Dell'Antonio, E. Dal Cin, A. Rubartelli, and M. R. Zocchi. 2002. NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J. Immunol. 168:95.
46. Takeda, K., H. Oshima, Y. Hayakawa, H. Akiba, M. Atsuta, T. Kobata, K. Kobayashi, M. Ito, H. Yagita, and K. Okumura. 2000. CD27-mediated activation of murine NK cells. J. Immunol. 164:1741.
47. Takeda, K., H. Tsutsui, T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Okamura, K. Nakanishi, and S. Akira. 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8:383.
48. + CTL in vivo. J. Immunol. 167:5027.
49. Billiau, A. D., H. Sefrioui, L. Overbergh, O. Rutgeerts, J. Goebels, C. Mathieu, and M. Waer. 2001. Transforming growth factor-β inhibits lymphokine activated killer cytotoxicity of bone marrow cells: implications for the graft-versus-leukemia effect in irradiation allogeneic bone marrow chimeras. Transplantation 71:292.
50. 1. J. Exp. Med. 194:809.
51. + T cells induced by dendritic cell stimulation are most sensitive to transforming growth factor-β: implications for dendritic cell immunization against cancer. Clin. Immunol. 102:96.
52. Kikuchi, T., M. A. Moore, and R. G. Crystal. 2000. Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96:91.
53. Candido, K. A., K. Shimizu, J. C. McLaughlin, R. Kunkel, J. A. Fuller, B. G. Redman, E. K. Thomas, B. J. Nickoloff, and J. J. Mule. 2001. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res. 61:228.
54. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
55. Suss, G., and K. Shortman. 1996. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183:1789.
56. Kronin, V., K. Winkel, G. Suss, A. Kelso, W. Heath, J. Kirberg, H. Von Boehmer, and K. Shortman. 1996. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J. Immunol. 157:3819.
57. Pulendran, B., J. L. Smith, G. Caspary, K. Brasel, D. Pettit, E. Maraskovsky, and C. R. Maliszewski. 1999. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA 96:1036.
58. + dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J. Exp. Med. 189:593.
59. - dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192:1685.